What one pandemic can teach us in facing another : AIDS

Secondary Logo

Journal Logo


What one pandemic can teach us in facing another

El-Sadr, Wafaa M.

Author Information
AIDS 34(12):p 1757-1759, October 1, 2020. | DOI: 10.1097/QAD.0000000000002636
  • Open

Almost exactly 39 years ago, the US Centers for Disease Control reported five cases of Pneumocystis carinii pneumonia among previously healthy gay men [1]. By the end of 1985, HIV was reported from every region in the world. Three decades later, 75 million people have acquired HIV and about 32 million have died from it [2].

HIV was the first pandemic that shaped my career – as it has for so many of my peers. Indeed, it fundamentally changed how we think about and respond to major health threats. HIV continues to be a clarion call – for countless scientists, health providers and community advocates around the world. And, sadly, four decades on, this pandemic still rages across the globe.

Today, for the first time in history, the world is experiencing two pandemics at the same time. What are the similarities and differences between the two pandemics? Are there lessons learned from confronting HIV that should guide the response to COVID-19 pandemic?

In terms of similarities, both pandemics are caused by zoonotic viruses. For HIV, research confirmed that the virus was transmitted from nonhuman primates to humans while SARS-CoV-2 is thought to have originated in bats [3,4]. In addition, both viruses are transmitted from person to person. The predominance of HIV transmission through sexual route and via injection drug use has resulted in profound stigma associated with it [5–7]. At the same time, COVID-19-related stigma has already been noted, including blaming outsiders [8]. Another similarity is that both epidemics have shed light on gaps in health systems. HIV, as a chronic communicable disease, required a transformation from a focus on acute care to be able to deliver on the chronic and ongoing needs of people living with HIV [9,10]. The COVID-19 pandemic, in contrast, has highlighted the fragility of surveillance and contact tracing systems, the paucity of measures to protect health providers, and the limited infrastructure for advanced care [11–14].

The good news is that the decades of struggles in confronting the HIV epidemic provide important lessons relevant to the control of the COVID-19 pandemic.

Firstly, political leadership is critically important. The early denial of the HIV epidemic in South Africa and the United States resulted in unnecessary loss of life [15–17]. Early denial of the risk of COVID-19 by leadership in the United States resulted in it leading the world in the number of cases and deaths. Similar reluctance in Brazil has resulted in the country leading all Latin American countries in the number of COVID-19 cases with an alarming number of deaths [18,19].

Secondly, perhaps the most durable legacy of the HIV response is the recognition of the critical importance of engaging communities, whether through the early voices of gay advocates in the United States or the vibrant participation of people living with HIV as peer educators around the world [20,21]. It has rapidly become evident that COVID-19 is disproportionately affecting African Americans and Latinos in the United States, with data showing them to be twice as likely to die from COVID-19. Similar adverse impacts have been noted among vulnerable populations in country after country around the world. We need to take the lessons learned from HIV and work to engage the communities most severely impacted by COVID-19.

Thirdly, it is widely acknowledged that the successful global response to the HIV epidemic was because of strengthening all pillars of the health system [22]. Addressing the need for lifelong treatment for HIV required investment in laboratory and medication procurement systems, training and mentorship of diverse health cadres and development of innovative models of care. A similar comprehensive approach is needed in order to ensure an effective response to COVID-19.

Fourthly, while during the early desperate years of the HIV epidemic, advocates reached for unproven treatment, they quickly became strong supporters of science-based interventions [23–25]. The harm caused by unproven HIV treatments should inspire caution and motivate a commitment to rigorous science in evaluating potential treatments and preventive measures for COVID-19.

Fifthly, the HIV epidemic showed us the importance of using data to inform action. National surveys in African countries provide this kind of granular data [26]. COVID-19 data from New York City, as another example, point to specific zip codes with the highest burden of COVID-19 [27]. These are the areas where we must focus our efforts in order to achieve equity, where intensive outreach is needed, and where testing sites and treatment resources should be situated to allow for rapid identification of cases.

Lastly, epidemics thrive on mistrust and myths. Conspiracy theories about HIV has jeopardized lives by provoking reluctance to get tested or to initiate treatment. As we face the COVID-19 epidemic, it behoves us to take the lessons from HIV to heart and identify trusted spokespersons armed with accurate information who can reach the affected populations with reliable information.

Experiencing two concomitant pandemics is unprecedented. Although attention has shifted to COVID-19, I fear we risk forgetting that the HIV pandemic still affects millions of people. We risk turning our attention to the issue of the moment, neglecting other health threats that people face. With a generation of experience as our guide, I am hopeful that the lessons learned from the first pandemic that defined my career can help bring the second one under control and with far fewer lives lost.


The author gratefully acknowledge inputs from Jessica Justman and Joey Platt.

Conflicts of interest

There are no conflicts of interest.


1. CDCPneumocystis pneumonia – Los Angeles. MMWR 1981; 30:250252.
2. UNAIDS. Global HIV & AIDS statistics — 2020 fact sheet. Available at: https://www.unaids.org/en/resources/fact-sheet [Accessed 13 June 2020]
3. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 2011; 1:a006841.
4. Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci 2020; 16:16861697.
5. Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend 2019; 198:8086.
6. Shannon K, Crago AL, Baral SD, Bekker LG, Kerrigan D, Decker MR, et al. The global response and unmet actions for HIV and sex workers. Lancet 2018; 392:698710.
7. Zhang C, Li X, Liu Y, Qiao S, Zhang L, Zhou Y, et al. Stigma against people living with HIV/AIDS in China: does the route of infection matter?. PLoS One 2016; 11:e0151078.
8. Human Rights Watch. Covid-19 fueling anti-Asian Racism and Xenophobia Worldwide National Action Plans Needed to Counter Intolerance. Available at: https://www.hrw.org/news/2020/05/12/covid-19-fueling-antiasian-racism-and-xenophobia-worldwide. [Accessed 13 June 2020]
9. El-Sadr WM, Rabkin M, DeCock KM. Population health and individualized care in the global AIDS response: synergy or conflict?. AIDS 2016; 30:21452148.
10. Rabkin M, El-Sadr WM. Why reinvent the wheel? Leveraging the lessons of HIV scale-up to confront non-communicable diseases. Glob Public Health 2011; 6:247256.
11. Pisa, M. COVID-19, Information Problems, and Digital Surveillance (March 20, 2020). In Commentary & Analysis. Center for Global Development. Available at: https://www.cgdev.org/blog/covid-19-information-problems-and-digital-surveillance. [Accessed 13 June 2020)]
12. Kluge HHP, Wickramasinghe K, Rippin HL, Mendes R, Peters DH, Kontsevaya A, Breda J. Prevention and control of noncommunicable diseases in the COVID-19 response. Lancet 2020; 395:16781680.
13. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020; 323:15451546.
14. Phua J, Weng L, Ling L, Egi M, Lim C-M, Vasishta J, et al. Asian Critical Care Trials GroupIntensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations [published correction appears in Lancet Respir Med 2020 May;8(5):e42]. Lancet Respir Med 2020; 8:506517.
15. Goodman, JD. How delays and unheeded warnings hindered New York's virus fight. New York Times. Available at: https://www.nytimes.com/2020/04/08/nyregion/new-york-coronavirus-response-delays.html [Accessed 13 June 2020]
16. Abutaleb Y, Dawsey J, Nakashima E, Miller G. The US was beset with denial and and dysfunction as the coronavirus raged. Washington Post. Available at: https://www.washingtonpost.com/national-security/2020/04/04/coronavirus-government-dysfunction/?arc404=true [Accessed 13 June 2020]
17. Niazi A. COVID-19 pandemic: politicking and denial of world leaders. Modern Diplomacy. Available at: https://moderndiplomacy.eu/2020/05/05/covid-19-pandemic-politicking-and-denial-of-world-leaders/. [Accessed 13 June 2020]
18. Kemeny R. Bolsonaro's denial of coronavirus puts the country at risk. The World. Available at: https://www.pri.org/stories/2020-04-14/bolsonaro-s-denial-coronavirus-puts-country-risk. [Accessed 13 June 2020]
19. Milz, T. Coronavirus: Brazil headed for catastrophe. 5 May 2020. DW. Available at: https://www.dw.com/en/coronavirus-brazilheaded-for-catastrophe/a-53502907. [Accessed 13 June 2020]
20. Mathews A, Farley S, Blumberg M, Knight K, Hightow-Weidman L, Muessig K, et al. HIV cure research community engagement in North Carolina: a mixed-methods evaluation of a crowdsourcing contest. J Virus Erad 2017; 3:223228.
21. Lo YR, Chu C, Ananworanich J, Excler JL, Tucker JD. Stakeholder engagement in HIV cure research: lessons learned from other HIV interventions and the way forward. AIDS Patient Care STDS 2015; 29:389399.
22. Rabkin M, El-Sadr WM, De Cock KM, Bellagio HIV/Health Systems Working Group1. The impact of HIV scale-up on health systems: A priority research agenda. J Acquir Immune Defic Syndr 2009; 52 Suppl 1:S6-11.
23. Havlir DV, Gilbert K, Bennett K, Collier AC, Hirsch MS, Tebas P. ∗and the ACTG 5025 Study TeamEffects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS 2001; 15:13791388.
24. Kaplan LD, Wolfe, PR, Volberding, PA, Feorino, P, Levy, JA, Abrams, DI. Lack of response to suramin in patients with AIDS and AIDS-related complex. Am J Med 1987: 615–620.
25. Centers for Disease Control and Prevention. CDC HIV Evaluation. (2019, July). Available at: https://www.cdc.gov/hiv/programresources/evaluation.html#trend. [Accessed 13 June 2020]
26. ICAP at Columbia University. (2020). The PHIA Project. Available at: https://phia.icap.columbia.edu/. [Accessed 15 June 2020]
27. New York City Department of Health and Mental Hygiene. (2020) COVID-19: Data by ZIP Code of Residence. Available at: https://www1.nyc.gov/site/doh/covid/covid-19-data.page. [Accessed 13 June 2020]

COVID-19 pandemic; HIV pandemic, lessons learned

Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.